PERTH, Australia – Auckland, New Zealand-based CuroNZ has begun a small proof-of-concept study in epilepsy for a cell-penetrating peptide that crosses the blood-brain barrier.
PERTH, Australia – Respirion Pharmaceuticals Pty Ltd. is the first investment in Western Australia by the Medical Research Commercialization Fund's Biomedical Translation Fund (MRCF BTF). The new Perth-based biotech company is developing an antibiotic therapy that could be life-changing for patients with cystic fibrosis.
PERTH, Australia – Respirion Pharmaceuticals Pty Ltd. is the first investment in Western Australia by the Medical Research Commercialization Fund's Biomedical Translation Fund (MRCF BTF). The new Perth-based biotech company is developing an antibiotic therapy that could be life-changing for patients with cystic fibrosis.
PERTH, Australia – Auckland, New Zealand-based CuroNZ has begun a small proof-of-concept study in epilepsy for a cell-penetrating peptide that crosses the blood-brain barrier.
